The safety and efficacy of Belviq were evaluated in three randomized, placebo-controlled trials that included nearly 8, 000 obese and overweight patients, with and without type 2 diabetes, treated for 52 to 104 weeks.
FORBES: Arena Obesity Drug Approval Looks Like Best-Case Scenario